Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors

Published:2019-05 Issue:5 Volume:42 Page:413-420
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Shah Hiral A.,Fischer James H.,Venepalli Neeta K.,Danciu Oana C.,Christian Sonia,Russell Meredith J.,Liu Li C.,Zacny James P.,Dudek Arkadiusz Z.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference29 articles.

1. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis;Hicklin;J Clin Oncol,2005

2. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma;Sonpavde;Expert Opin Investig Drugs,2008

3. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;van der Graaf;Lancet,2012

4. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

5. The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway;Wang;Cancer Res,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor vasculature associated nanomedicine strategies;Coordination Chemistry Reviews;2024-12

2. Knowledge mapping of AURKA in Oncology：An advanced Bibliometric analysis (1998–2023);Heliyon;2024-06

3. Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA;Annals of Medicine;2024-05-13

4. The two sides of chromosomal instability: drivers and brakes in cancer;Signal Transduction and Targeted Therapy;2024-03-29

5. Seize the engine: Emerging cell cycle targets in breast cancer;Clinical and Translational Medicine;2024-01